The incretin hormones: From scientific discovery to practical therapeutics

Diabetologia

Volumn 55, Issue 7, 2012, Pages 1865-1868

  Mudaliar, S ^a,b   Henry, R R ^a,b  

^a VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Gip; GLP 1; Incretin hormones

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; INCRETIN; INSULIN; LINAGLIPTIN; LIRAGLUTIDE; PLACEBO; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA; VILDAGLIPTIN;

ANTIDIABETIC ACTIVITY; ARTICLE; BODY WEIGHT; CARBOHYDRATE INTAKE; DIABETES CONTROL; DIET RESTRICTION; DRUG EFFICACY; DRUG TREATMENT FAILURE; GLUCOSE BLOOD LEVEL; HORMONE RELEASE; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN RELEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUTRIENT; PANCREAS ISLET BETA CELL; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; REMISSION; SATIETY; STOMACH EMPTYING; WEIGHT REDUCTION;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSE; HUMANS; HYPERGLYCEMIA; MALE; PEPTIDE FRAGMENTS;

EID: 84866393205     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-012-2561-x     Document Type: Article

References (18)

1. Nauck M, Stöckmann F, Ebert R, Creutzfeldt W (1986) Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 29:46-52
2. Kreymann B, Williams G, Ghatei MA, Bloom SR (1987) Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 2:1300-1304
3. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W (1993) Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 91:301-307
4. Nauck MA, Kleine N, Ørskov C, Holst JJ, Willms B, Creutzfeldt W (1993) Normalisation of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 36:741-744
5. Nauck MA (2011) Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications. Am J Med 124(1 Suppl):S3-S18
6. Nauck MA, Vardarli I, Deacon CF, Holst JJ, Meier JJ (2011) Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down? Diabetologia 54:10-18
7. Nauck MA, Siemsglüss J, Orskov C, Holst JJ (1996) Release of glucagon-like peptide 1 (GLP-1 [7-36 amide]), gastric inhibitory polypeptide (GIP) and insulin in response to oral glucose after upper and lower intestinal resections. Z Gastroenterol 34:159-166
8. Mortensen K, Christensen LL, Holst JJ, Orskov C (2003) GLP-1 and GIP are colocalized in a subset of endocrine cells in the small intestine. Regul Pept 114:189-196
9. Mentis N, Vardarli I, Köthe LD et al (2011) GIP does not potentiate the antidiabetic effects of GLP-1 in hyperglycemic patients with type 2 diabetes. Diabetes 60:1270-1276
10. Drucker DJ, Nauck MA (2006) The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368:1696-1705
11. Chia CW, Egan JM (2008) Incretin-based therapies in type 2 diabetes mellitus. J Clin Endocrinol Metab 93:3703-3716
12. Waget A, Cabou C, Masseboeuf M et al (2011) Physiological and pharmacological mechanisms through which the DPP-4 inhibitor sitagliptin regulates glycemia in mice. Endocrinology 152:3018-3029
13. Fonseca V, Schweizer A, Albrecht D, Baron MA, Chang I, Dejager S (2007) Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia 50:1148-1155
14. Fonseca V, Baron M, Shao Q, Dejager S (2008) Sustained efficacy and reduced hypoglycemia during one year of treatment with vildagliptin added to insulin in patients with type 2 diabetes mellitus. Horm Metab Res 40:427-430
15. Salehi M, Prigeon RL, D'Alessio DA (2011) Gastric bypass surgery enhances glucagon-like peptide 1-stimulated postprandial insulin secretion in humans. Diabetes 60:2308-2314
16. Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M (2008) Cardioprotective and vasodilatory actions of glucagonlike peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 117:2340-2350
17. Li Y, Duffy KB, Ottinger MA et al (2010) GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease. J Alzheimers Dis 19:1205-1219
18. Drucker DJ, Sherman SI, Bergenstal RM, Buse JB (2011) The safety of incretin-based therapies-review of the scientific evidence. J Clin Endocrinol Metab 96:2027-2031